Inhibitors targeting components of the PI3K/Akt/mTOR pathway have shown promise in preclinical studies, suggesting that combinatorial strategies utilizing these inhibitors might improve treatment outcomes in NB cases resistant to standard therapies [54,55]. The gene discussed is AKT1; the disease is neuroblastoma.